ASCO 2015: Obinutuzumab Doubles Remission Duration in Patients With Relapsed, Indolent Non-Hodgkin Lymphoma
Interim analysis of a phase III study finds that adding the new anti-CD20 monoclonal antibody obinutuzumab to standard bendamustine chemotherapy significantly delays progression of indolent non-Hodgki...
Author: EMJ
Added: 06/03/2015
Source: Oncology Tube - Category: Cancer & Oncology Source Type: podcasts